Trontinemab for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 3 registered trials.

Why this status

  1. 12 Sep 2025: Trial registered, NCT07169578
  2. 17 Sep 2025: Trial started, NCT07169578
  3. 21 Jul 2026: Trial registered, NCT07717411
  4. 2 Oct 2026: Trial started, NCT07717411

The trials

NCT04639050: Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

State
Under way
Phase
Phase 1 and Phase 2
People
241 taking part
Started
15 Mar 2021
Primary completion
31 Jul 2027
Arms
Part 1 (Dose Finding) Cohort 1: Dose Level 1 of RO7126209, Part 1 (Dose Finding) Cohort 2: Dose Level 2 of RO7126209, Part 1 (Dose Finding) Cohort 3: Dose Level 3 of RO7126209, Part 1 (Dose Finding) Cohort 4: Dose Level 4 of RO7126209, Part 1 (Dose Finding) Cohort 5: Dose Level 5 of RO7126209, Part 2 (Expansion) Cohort 1: Dose Level 3 of RO7126209, Part 2 (Expansion) Cohort 2: Dose Level 4 of RO7126209, Part 2 (Expansion) Cohort 3: Dose Level 5 of RO7126209, Part 3 (Dose/Frequency/Pharmacodynamic (PD) Relationship): Dose Level 1: RO7126209, Part 3 Dose/Frequency/PD Relationship: Dose Level 2: RO7126209, Part 4: Open Label Extension (OLE)
Results
None posted
  1. 20 Nov 2020: Trial registered
  2. 15 Mar 2021: Trial started

NCT07169578: A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

State
Under way
Phase
Phase 3
People
1,101 taking part
Started
17 Sep 2025
Primary completion
16 Feb 2028
Arms
Trontinemab
Results
None posted
  1. 12 Sep 2025: Trial registered
  2. 17 Sep 2025: Trial started

NCT07717411: A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

State
Under way
Phase
Phase 3
People
1,600 planned
Started
2 Oct 2026
Primary completion
30 Jul 2032
Arms
Trontinemab
Results
None posted
  1. 21 Jul 2026: Trial registered
  2. 2 Oct 2026: Trial started

How the status changed

  1. 16 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.